Full Press Release Details
MINNEAPOLIS , March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-certification as CE-IVD as of March 22, 2021 . The EPI-CE test will be performed immediately in our Munich ISO 15189 accredited clinical laboratory and be made available throughout Europe through various distribution channels.
These findings can have significant implications for both clinical and economic outcomes. According to Alexander Kretschmer , M.D., Assistant Professor of Urology at Ludwig-Maximilians-University Munich, "From a clinical perspective, deferring biopsy can help a patient avoid the undesirable complications from a biopsy, such as pain, hematuria, infection and potentially hospitalization. Many patients are frightened to undergo the biopsy procedure; however, introducing an EPI test can identify which patients should proceed to biopsy, and which patients can avoid biopsy, so it's really about performing the procedure for the right patient at the right time."
For more information on how to order tests, please contact us at [email protected] .
About Bio-Techne Corporation (NASDAQ: TECH )
Contact: David Clair , Senior Director, Investor Relations & Corporate Development
[email protected]
SOURCE Bio-Techne Corporation